Despite the devastating effects that osteoporosis can have on a patient’s quality of life, most of the data used to inform the treatment of osteoporosis has been extrapolated from studies of postmenopausal women and does not include special populations, who have a significant risk of osteoporosis-related morbidity and mortality. This session will focus on updated guidelines on osteoporosis treatment and discuss their use in specific patient populations, including men, patients with steroid-induced osteoporosis, geriatric patients, and children. Updates regarding the removal of the boxed warning for parathyroid hormone (PTH) analogs, as well as the post-marketing surveillance literature that led to the warning’s removal, are discussed, as are suggestions for moving forward with the use of PTH analogs in osteoporosis treatment.
This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) and Board Certified Geriatric Pharmacist (BCGP) recertification credit.
The BCACP and BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified Ambulatory Care or Geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP, BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCACP/BCGP posttests. For participants who have not purchased access to the posttests, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025.